Get the Stockscreener App
0.32
3.03%
-0.01
Pre-market:
.32
Acurx Pharmaceuticals Inc stock is traded at $0.32, with a volume of 211.77K.
It is down -3.03% in the last 24 hours and down -48.67% over the past month.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
See More
Previous Close:
$0.33
Open:
$0.335
24h Volume:
211.77K
Relative Volume:
0.62
Market Cap:
$7.05M
Revenue:
-
Net Income/Loss:
$-14.58M
P/E Ratio:
-0.2783
EPS:
-1.15
Net Cash Flow:
$-9.80M
1W Performance:
-21.65%
1M Performance:
-48.67%
6M Performance:
-85.12%
1Y Performance:
-83.67%
1-Day Range:
$0.32
$0.3443
1-Week Range:
$0.32
$0.4105
52-Week Range:
$0.32
$3.325
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Name
Acurx Pharmaceuticals Inc
Sector
Industry
Phone
917-533-1469
Address
259 LIBERTY AVENUE, STATEN ISLAND
Compare ACXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
0.32 | 7.05M | 0 | -14.58M | -9.80M | -1.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Acurx Pharmaceuticals Inc Stock (ACXP) Latest News
Acurx Pharmaceuticals announces resale of 8.4M shares - MSN
10 Micro-Cap Stocks Insiders Were Buying in Q1 2025 - Insider Monkey
Acurx Pharmaceuticals, Inc. (ACXP): Insider Were Buying In Q1 2025 - Insider Monkey
ACXP stock touches 52-week low at $0.4 amid sharp annual decline - Investing.com Canada
Acurx Pharmaceuticals Inc (ACXP) Q4 2024 Earnings Call Highlights: Advancing Antibiotic Trials ... By GuruFocus - Investing.com Canada
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know - MSN
HC Wainwright Issues Positive Forecast for ACXP Earnings - Defense World
FY2029 Earnings Forecast for ACXP Issued By HC Wainwright - Defense World
HC Wainwright Reaffirms “Buy” Rating for Acurx Pharmaceuticals (NASDAQ:ACXP) - Defense World
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2024 Earnings Call Transcript - Insider Monkey
Acurx Pharmaceuticals Reports 2024 Results and Advances Trials - TipRanks
Acurx Pharmaceuticals’ Optimistic Earnings Call Highlights Clinical Progress - TipRanks
Earnings call transcript: Acurx Pharmaceuticals Q4 2024 sees narrower EPS loss - Investing.com Canada
ACXP stock touches 52-week low at $0.43 amid market challenges - Investing.com UK
Acurx Pharmaceuticals, Inc Full Year Loss Narrows - Nasdaq
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - Yahoo Finance
Earnings Scheduled For March 18, 2025 - Benzinga
Acurx Pharmaceuticals, Inc. SEC 10-K Report - TradingView
New to The Street & Sight & Sound's Visionaries Series Premieres Tomorrow on Bloomberg at 6:30 PM EST, Featuring Acurx Pharmaceuticals NASDAQ:ACXP - Milton Daily Standard
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Growth in Short Interest - Defense World
Acurx Pharmaceuticals (ACXP) Projected to Post Quarterly Earnings on Tuesday - Defense World
Acurx Pharmaceuticals Announces Closing of $1.1 Million Registered Direct Offering -March 10, 2025 at 05:37 pm EDT - MarketScreener
ACXPAcurx Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
Dow Dips Over 250 Points; Genesco Shares Plunge After Q4 Results - Benzinga
Why Acurx Pharmaceuticals (ACXP) Shares Are Down 30% - Benzinga
Acurx Pharmaceuticals Launches $1.1 Million Registered Direct Offering; Shares Fall -March 07, 2025 at 10:07 am EST - Marketscreener.com
Nasdaq Gains 100 Points; US Economy Adds Fewer Jobs Than Projected - Benzinga
Acurx Pharmaceuticals stock sinks on $1.1M direct offering - MSN
Acurx Pharmaceuticals Announces $1.1 Million Registered Direct Offering -March 07, 2025 at 08:14 am EST - Marketscreener.com
Can This $1.1M Funding Keep Acurx's Antibiotic Development on Track? - StockTitan
Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering - Yahoo Finance
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Decrease in Short Interest - Defense World
ACXP stock touches 52-week low at $0.66 amid market challenges - Investing.com
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics - Yahoo Finance
Can Acurx's Antibiotic Revolutionize C. Difficile Treatment? New Microbiome Data Suggests Yes - Stock Titan
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update - Yahoo Finance
What's Next for Acurx's Antibiotic Pipeline? March Earnings Call Will Reveal Development Progress - Stock Titan
Biotech Alert: Searches spiking for these stocks today - TipRanks
Acurx’s ibezapolstat shows selective bacterial targeting By Investing.com - Investing.com Nigeria
Acurx Pharmaceuticals Advances To Phase 3 Trials For C. Difficile Infection, Stock Down - Nasdaq
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the - Digital More
Acurx's ibezapolstat shows selective bacterial targeting By Investing.com - Investing.com South Africa
Acurx's ibezapolstat shows selective bacterial targeting - Investing.com India
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI - Longview News-Journal
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative… - Informazione.it
Can This New Antibiotic Finally Solve the C. Difficile Recurrence Problem? Study Says Yes - Stock Titan
ACXP stock touches 52-week low at $0.67 amid market challenges - Investing.com UK
Acurx Pharmaceuticals secures Japanese patent for antibiotics By Investing.com - Investing.com South Africa
Acurx Pharmaceuticals secures Japanese patent for antibiotics - Investing.com India
Dual Victory for Acurx: Japanese Patent Grant Follows EMA's Green Light for Phase 3 Antibiotic Trial - StockTitan
New to the Street to Broadcast Show 627 on Bloomberg Television at 6:30 PM EST Today as Sponsored Programming - StreetInsider.com
Acurx Pharmaceuticals Inc Stock (ACXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):